Latest Posts:

Sorry, no posts matched your criteria.

Follow Us:

Back To Top

JOIN OUR EFFORTS TO

Design the next generation of synthetic lethality

by launching a science company.

Cancer is an evolution machine. Decades before diagnosis, a multitude of different clones, carrying differential sets of mutations are setting the scene that makes almost any targeted therapy obsolete. The new era of personalised medicine and of immense knowledge of the genetics, epigenetics, gene expression, metabolomics, and clonal evolution of tumours, converges with the completion of flagship synthetic lethality studies, interrogating pan-cancer functional genomics. However, target discovery still focuses on finding targeted therapies against well-established cancer drivers from which cancer has already evolved out of, even years before diagnosis. This results in limited response rates in the clinic and quick evolution of resistance for targets against such drivers for example BRCA targeted PARP inhibitors.

approaches we’re considering

We are stopping the chase for moving targets by building a highly advanced drug discovery machine, that leverages the wealth of data of this new era to identify vulnerable mechanisms that cancer cannot evolve out of and the specific context in which they are effective.

To achieve that, we identify cancer systems biology and specific mechanisms of irreversible cancer dependencies through advanced computational methods.

Our current approach sets the bar very high, to produce complete and sustained therapeutic responses. We have invented methods that have already produced potential candidates with strong independent validation.

Join us to create a company that will bring novel curative therapies to cancer patients.

who should apply

We are looking for doctoral or postdoctoral experience in systems biology, computational genomics and oncology as well as the technical skills detailed below. You should have an absolute drive to develop therapies for the many people in need. You must be an entrepreneurial, inventive, resourceful, and resilient professional that questions conventional thinking and creates teams, networks, and resources to solve complex problems fast. An individual that despite the knowledge of the incredibly challenging task ahead is still determined to make things happen.

You should have experience in (a mix of):
●  Synthetic lethality
●  Target discovery
●  Omics subtyping of cancer
●  Clonal evolution genomics
●  Data science
●  Machine learning
●  Analytical pipeline development
●  Functional genomics
●  Statistics

our offer

Your role will start as a Founder within DSV under our unique framework for venture creation. It’s a full time role working across market analysis, science and customer development together with the DSV team before incorporating your own start-up within 6 months (give or take a couple of months) with pre-seed investment from DSV.

We already have a number of exciting projects being developed in this space and expect to make first investments into newly formed startups and founding teams by the end of the year. 

Our partnership with Cancer Research UK means that your work will also be supported by the world’s largest independent funder of cancer research. Further information about the DSV-CRUK partnership here.

No prior idea or IP required.

Cancer is an evolution machine. Decades before diagnosis, a multitude of different clones, carrying differential sets of mutations are setting the scene that makes almost any targeted therapy obsolete. The new era of personalised medicine and of immense knowledge of the genetics, epigenetics, gene expression, metabolomics, and clonal evolution of tumours, converges with the completion of flagship synthetic lethality studies, interrogating pan-cancer functional genomics. However, target discovery still focuses on finding targeted therapies against well-established cancer drivers from which cancer has already evolved out of, even years before diagnosis. This results in limited response rates in the clinic and quick evolution of resistance for targets against such drivers for example BRCA targeted PARP inhibitors.

approaches we’re considering

We are stopping the chase for moving targets by building a highly advanced drug discovery machine, that leverages the wealth of data of this new era to identify vulnerable mechanisms that cancer cannot evolve out of and the specific context in which they are effective.

To achieve that, we identify cancer systems biology and specific mechanisms of irreversible cancer dependencies through advanced computational methods.

Our current approach sets the bar very high, to produce complete and sustained therapeutic responses. We have invented methods that have already produced potential candidates with strong independent validation.

Join us to create a company that will bring novel curative therapies to cancer patients.

who should apply

We are looking for doctoral or postdoctoral experience in systems biology, computational genomics and oncology as well as the technical skills detailed below. You should have an absolute drive to develop therapies for the many people in need. You must be an entrepreneurial, inventive, resourceful, and resilient professional that questions conventional thinking and creates teams, networks, and resources to solve complex problems fast. An individual that despite the knowledge of the incredibly challenging task ahead is still determined to make things happen.

You should have experience in (a mix of):
●  Synthetic lethality
●  Target discovery
●  Omics subtyping of cancer
●  Clonal evolution genomics
●  Data science
●  Machine learning
●  Analytical pipeline development
●  Functional genomics
●  Statistics

our offer

Your role will start as a Founder within DSV under our unique framework for venture creation. It’s a full time role working across market analysis, science and customer development together with the DSV team before incorporating your own start-up within 6 months (give or take a couple of months) with pre-seed investment from DSV.

We already have a number of exciting projects being developed in this space and expect to make first investments into newly formed startups and founding teams by the end of the year. 

Our partnership with Cancer Research UK means that your work will also be supported by the world’s largest independent funder of cancer research. Further information about the DSV-CRUK partnership here.

No prior idea or IP required.

Interviews ongoing

Start date asap, places allocated as soon as the right fit is found.

Interviews ongoing

Start date asap, places allocated as soon as the right fit is found.

current founders

Andreas: background in Cancer Drug Discovery, Diagnostics and Pharma Corporate Business Development. He has been twice CEO of successful companies in the regenerative medicine and Alzheimer’s field. He is working on leveraging synthetic lethality, clinical omics data and clonal architecture of tumour evolution to discover previously unknown targets that can achieve more efficient and lasting responses in patients and address the most challenging problem in cancer therapy, tumour heterogeneity.

Andreas: background in Cancer Drug Discovery, Diagnostics and Pharma Corporate Business Development. He has been twice CEO of successful companies in the regenerative medicine and Alzheimer’s field. He is working on leveraging synthetic lethality, clinical omics data and clonal architecture of tumour evolution to discover previously unknown targets that can achieve more efficient and lasting responses in patients and address the most challenging problem in cancer therapy, tumour heterogeneity.